Akeso’s ivonescimab plus chemo beats Imfinzi plus chemo in overall survival terms in head-to-head Phase III trial in untreated biliary tract cancer.
Akeso’s ivonescimab plus chemo beats Imfinzi plus chemo in overall survival terms in head-to-head Phase III trial in untreated biliary tract cancer.